title: Global fibrinolytic capacity in colorectal cancer: a new clue to occult fibrinolysis.
abstract: Hemostatic disorders in cancer patients range from asymptomatic laboratory changes to massive thromboembolism or hemorrhage. Routine laboratory tests often fail to identify patients at high risk for hemostatic complications. The postoperative risk of thromboembolic events in colorectal cancer was reported as approximately 2% to 5%. A new diagnostic test was used to assess global fibrinolytic activity, which may detect occult fibrinolysis or disseminated intravascular coagulation in patients with colorectal cancer. Twenty patients with colorectal cancer and 20 healthy control subjects were involved. Using standard silicated fibrin pellets and tissue plasminogen activator, the fibrinolytic capacity of the plasma samples was detected with the amount of D-dimer produced before the reaction was stopped by adding aprotinin to the medium. Mean global fibrinolytic capacity was increased in patients before and after surgery when compared to controls (p = 0.002, p = 0.001, respectively). In conclusion, a hemostatic imbalance was detected toward primary fibrinolysis in the preoperative period and low-grade disseminated intravascular coagulation postoperatively.
authors.affiliation: Department of Rheumatology, Fatih University Faculty of Medicine, Ankara, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Ozturk
authors.forename: Neriman
authors.initials: N
authors.lastname: Sengul
authors.forename: Mehmet
authors.initials: M
authors.lastname: Dagli
authors.forename: Ali
authors.initials: A
authors.lastname: Kosar
authors.forename: Nüket
authors.initials: N
authors.lastname: Bavbek
mesh_terms: D007611:Aprotinin / Q000494:pharmacology; D003110:Colonic Neoplasms / Q000097:blood* / Q000601:surgery; D004211:Disseminated Intravascular Coagulation / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects; D006474:Hemorrhagic Disorders / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D008297:Male; D011183:Postoperative Complications / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D011184:Postoperative Period; D011517:Prothrombin Time; D012004:Rectal Neoplasms / Q000097:blood* / Q000601:surgery; D012306:Risk; D019851:Thrombophilia / Q000175:diagnosis / Q000209:etiology; D010959:Tissue Plasminogen Activator / Q000494:pharmacology; D020246:Venous Thrombosis / Q000097:blood / Q000209:etiology
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D005340:Fibrinogen; D007611:Aprotinin; D010959:Tissue Plasminogen Activator